Dextech Medical (DEX.SL) Stock Price

Dextech Medical Price

CLOSED
9.76
​
Market closed

Dextech Medical stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dextech Medical business model & stock analysis

Dextech Medical AB develops drug candidates for urological oncology, focusing on prostate cancer and other conditions. The company utilizes its patented GuaDex technology platform to create modified carbohydrate molecules combined with active substances. Its portfolio includes OsteoDex for bone metastases in castration-resistant prostate cancer, SomaDex targeting acromegaly and neuroendocrine tumors, and CatDex for bladder cancer treatment. The company holds patents or patent applications for these three drug candidates. Dextech Medical AB's primary revenue streams come from licensing its technology and drug candidates to pharmaceutical partners. The company's GuaDex platform and its drug candidates, OsteoDex, SomaDex, and CatDex, are marketed to biopharmaceutical companies seeking innovative treatments for urological oncology and related diseases. The firm's focus on prostate cancer, bone metastases, and bladder cancer creates a targeted market for its products. The company's business model relies on developing and commercializing its drug candidates through partnerships with established pharmaceutical companies. With only three drug candidates in its portfolio, Dextech Medical AB targets specific therapeutic areas within urological oncology, leveraging its patented GuaDex platform to attract potential partners in the biopharmaceutical industry.

Frequently asked questions about Dextech Medical

Converted at the current exchange rate, the Dextech Medical share trades at 0.88 EUR (9.76 SEK).

The revenue cannot currently be calculated for Dextech Medical.

The profit of Dextech Medical is -6.46 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Dextech Medical is currently -27.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dextech Medical stock.

The P/S cannot be calculated for Dextech Medical currently.

The Eulerpool Quality Score for Dextech Medical is 3/10.

The ISIN of Dextech Medical is SE0005881489. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Dextech Medical is DEX.SL. The ticker symbol is used to trade Dextech Medical shares on the stock exchange.

Fair ValueTerminal
9.08 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Sweden
Currency
SEK
Initial public offering
Jun 19, 2014
ISIN
SE0005881489
Cusip
W2378Y100
Market capitalization
180.46 M SEKMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
9.86
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-35.29 %
Last updated Nov 19, 2026, 3:49 AM

Dextech Medical Peer Group